Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bryologyx Inc. manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being examined by 1 distinct examiner, SCHMIDT, IZABELA MARIA, who is the busiest examiner with 1 busiest examiner pending action. The portfolio is currently restricted to 1 distinct art unit, suggesting a specialized pharmaceutical or biological focus.
For a practitioner, the success of the current pending portfolio is entirely dependent on the interaction with SCHMIDT, IZABELA MARIA. The presence of only 1 distinct examiner means that the practitioner does not need to coordinate between different examiner styles. However, it also means that the company's patent prospects are concentrated in a single individual's hands.
With 1 distinct art unit involved, the practitioner can focus on the specific precedents and technical nuances of that specific USPTO division. The fact that there is only 1 pending office action simplifies the management of the portfolio but increases the importance of this single prosecution. Strategic planning should prioritize the specific requirements and historical allowance patterns of SCHMIDT, IZABELA MARIA.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMIDT, IZABELA MARIA | 1 | 65.7% | +42.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18834562 | METHOD OF ADMINISTRATION OF BRYOSTATIN FOR THE INDUCTION OF TUMOR ASSOCIATED ANTIGENS | SCHMIDT, IZABELA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18834562 | METHOD OF ADMINISTRATION OF BRYOSTATIN FOR THE INDUCTION OF TUMOR ASSOCIATED ANTIGENS | SCHMIDT, IZABELA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18834562 | METHOD OF ADMINISTRATION OF BRYOSTATIN FOR THE INDUCTION OF TUMOR ASSOCIATED ANTIGENS | SCHMIDT, IZABELA MARIA | 1621 | §102§103§112 | Non-Final OA | — | Pending | Jul 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBryologyx Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Izabela Maria Schmidt has the most, with 1 of Bryologyx Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
